NCT02360579 · OUTCOME

Overall Survival

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma · Source last updated 2026-03-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Until death or up to 60 months

What was measured

Evaluate overall survival (OS)

Analysis population: The Full Analysis Set is defined as patients who received the lifileucel infusion that met product manufacturing specifications. Due to the small number of patients this outcome measure was not analyzed for Cohort 3 per the statistical analysis plan.

Groups in this outcome

Cohort 2

Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)

Cohort 4

Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)

Cohort 1

Non-cryopreserved LN-144 (Gen 1 infusion product)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort 2	66
Cohort 4	87
Cohort 1	20

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Cohort 2	15.6	Not reported	11.0	23.3	Not reported
Cohort 4	12.7	Not reported	8.3	17.8	Not reported
Cohort 1	12.9	Not reported	5.3	26.1	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
11.0
upper Limit
23.3
value
15.6
group Id
OG001
lower Limit
8.3
upper Limit
17.8
value
12.7
group Id
OG002
lower Limit
5.3
upper Limit
26.1
value
12.9

denoms

counts
group Id
OG000
value
66
group Id
OG001
value
87
group Id
OG002
value
20
units
Participants

description

Evaluate overall survival (OS)

dispersion Type

95% Confidence Interval

groups

description
Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
id
OG000
title
Cohort 2
description
Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
id
OG001
title
Cohort 4
description
Non-cryopreserved LN-144 (Gen 1 infusion product)
id
OG002
title
Cohort 1

param Type

MEDIAN

population Description

The Full Analysis Set is defined as patients who received the lifileucel infusion that met product manufacturing specifications. Due to the small number of patients this outcome measure was not analyzed for Cohort 3 per the statistical analysis plan.

reporting Status

POSTED

time Frame

Until death or up to 60 months

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice